Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. addition

ADDITION

Arthritis Differential DIagnostic validaTION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ADDITION project word cloud

Explore the words cloud of the ADDITION project. It provides you a very rough idea of what is the project "ADDITION" about.

cloud    infrastructure    ra    treatment    expenses    newly    inappropriate    genes    ineffective    leads    describes    central    osteoarthritis    few    signature    techniques    lab    feasibility    earlier    suffering    health    pcr    diagnostic    web    40    joints    500    validated    economic    provides    solution    involve    differential    90    diseases    distinction    huge    validate    patient    spondylarthropaties    collection    biopsy    rheumatoid    accuracy    procedure    ing    strategies    line    trancriptomic    inflammation    eular2010    functional    diagnosed    predict    marked    impacts    transportation    unsatisfactory    turnover    patients    serious    probabilities    efficacy    consists    cohort    incidence    ea    larger    arthritis    mistake    clinical    useless    1000    subclass    computing    adequacy    progression    2014    ua    clinically    vs    synovial    unjustified    140m    seronegative    treatments    acr    complemented    tool    clinicians    criterion    undifferentiated    mtx    kit    socio    prospective    annual    280m    ce    first    rheumakit    limited    group    methotrexate    market    logistics    therapeutic   

Project "ADDITION" data sheet

The following table provides information about the project.

Coordinator		 DNALYTICS 

Organization address
address: CHEMIN DU CYCLOTRON 6
city: OTTIGNIES LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Belgium [BE]
 Project website http://www.dnalytics.com. The RheumaKit online platform
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DNALYTICS BE (OTTIGNIES LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Arthritis, a group of diseases involving inflammation of joints with huge health and socio-economic impacts. Early Arthritis (EA) describes newly diagnosed arthritis (incidence 2/1000). An improved arthritis management requires to enhance the EA differential diagnostic efficacy and the adequacy of the therapeutic strategies. The earlier arthritis is addressed, the more likely its progression will be limited. A mistake in differential diagnostic leads to inappropriate treatments, resulting in useless expenses and serious side effects, unjustified. Current diagnostic techniques are unsatisfactory and the most used first line treatment, Methotrexate (MTX), is ineffective in about 40% of the patients. RheumaKit is a solution for clinicians for the early differential diagnostic of patients suffering from undifferentiated arthritis (UA, a subclass of EA). RheumaKit is based on a trancriptomic signature of about 100 genes complemented by 3 clinical factors. It provides a 90% accuracy for the Rheumatoid Arthritis (RA) vs non-RA distinction, far above the ACR/EULAR2010 criterion on the same patients. It also provides probabilities for Osteoarthritis and Seronegative Spondylarthropaties. The solution consists of a synovial biopsy collection and transportation kit (CE-marked May 2014), a central lab PCR procedure, and a web application computing the effective diagnostic on a cloud-computing infrastructure. Functional, technical, logistics aspects of RheumaKit have been validated. ADDITION aims at clinically validate on a larger patient cohort the existing RheumaKit signature for the differential diagnostic of most EA patients and validate the use of the existing RheumaKit signature as a tool to predict MTX response. ADDITION phase 2 will involve a prospective study on 500 to 1000 EA patients. The main phase 1 objectives are a feasibility study of the clinical and market aspects of ADDITION. The expected annual turnover is above 140M€-280M€ in EU within a few years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADDITION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADDITION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More